Dasan Pharmaceutical (CEO Ryu Hyeong-seon) announced on the 22nd that it has selected NH Investment & Securities as the lead manager for its KOSDAQ listing and is beginning the IPO process in earnest.
Dasan Pharmaceutical explained that it selected NH Investment & Securities as the lead manager due to its deep understanding of the pharmaceutical and bio industries, extensive experience in managing IPOs, and particularly its track record of IPOs of large bio companies.
Launched in 1996 as Dasan Medichem, Dasan Pharmaceutical has focused on the development and production of raw materials and finished pharmaceutical products for 29 years, focusing on R&D and facility expansion. By securing proprietary formulation technologies, including fluidized bed coating technology and drug delivery systems (DDS), the company is responding to the expanding global CDMO (contract development and manufacturing organization) market.
Dasan Pharmaceutical has established a mid- to long-term development master plan based on its capabilities in manufacturing pharmaceuticals in various dosage forms, including oral, injectable, and transdermal. In the injectable field, the company has secured safety and price competitiveness with a fat-dissolving injectable using plant-derived raw materials. It is also developing a long-acting injectable using its proprietary "microfluidics" technology. The company is also pursuing its cosmetic and therapeutic filler business as a new growth engine. In the transdermal field, the company plans to collaborate with research institutions to develop an innovative pipeline of treatments for atopic dermatitis and melanoma, utilizing patented polymer materials.
CEO Ryu Hyeong-seon said, “Through the IPO, we will platform our core technologies, expand our new formulation development and manufacturing capabilities, and strengthen our entry into overseas markets through localization, thereby leaping forward as a global CDMO specialist.”
You must be logged in to post a comment.